Multi-omics Biomarker Analysis Identifies Unique Immune Activation Signature in Pancreatic Cancer

Multi-omics Biomarker Analysis Identifies Unique Immune Activation Signature in Pancreatic Cancer

Case Studies

We describe a first-of-its-kind study using multi-omics biomarker approaches to demonstrate pharmacodynamic effects and immune modulation in pancreatic cancer. Biognosys’ proprietary platform for unbiased proteomics, TrueDiscovery™, allowed the identification of pharmacodynamic markers and elucidated the mechanism of action of therapies under clinical investigation.

Back to Resources overview

Contact

    By submitting this form, you confirm that you consent to Biognosys processing of your personal data for the purposes and in the manner as described in our Privacy Notice.

    Close banner

    New: Spectronaut® 19

    Unlock Your Data's True Story

    New: Spectronaut® 19

    Unlock Your Data's True Story

    Learn More